For decades, the standard of care for women in menopause was shaped by a single question: Is she symptomatic enough to treat? Hot flashes, sleep disruption, vaginal atrophy — these became the threshold. If a patient wasn’t complaining loudly enough, hormones weren’t on the table.

That framework was never grounded in the full body of evidence. And the providers who were trained inside it are now caring for women whose hormone decline is quietly driving outcomes across multiple organ systems — outcomes that show up in their neurology notes, their orthopedic referrals, their cardiology charts. The hormones are the missing link.

What Medical Training Got Wrong

The 2002 Women’s Health Initiative study didn’t just influence clinical guidelines — it shaped a generation of prescribing culture. Caution became the default. Hormone therapy was positioned as a short-term, symptom-specific intervention, and even that was to be used reluctantly.

The science has moved decisively beyond that era. The 2024 JAMA study by Manson et al. found that lower-dose, non-oral estrogen therapy was associated with reductions in overall mortality, breast cancer risk, colorectal cancer risk, congestive heart failure, and dementia.¹ On November 10, 2025, the FDA removed the black box warnings related to cardiovascular disease, breast cancer, and probable dementia that had been placed on estrogen products — a regulatory signal that the risk narrative inherited from 2002 no longer reflects the evidence.²

The question is no longer whether to consider hormones. It is whether providers have the training to prescribe them correctly.

Where Hormones Show Up in Outcomes

The Brain. Estrogen receptors are distributed throughout brain regions critical for memory, cognition, and mood regulation. Estrogen supports neuronal connectivity, reduces neuroinflammation, and enhances the production of acetylcholine — a neurotransmitter markedly depleted in Alzheimer’s disease. Research has demonstrated reductions of 19–22% in dementia risk with estrogen therapy, with greater benefit when initiated during perimenopause or early menopause.³ This timing effect matters clinically: the window for maximum neuroprotection is not indefinite, and delayed intervention reduces the potential benefit.

Bone and Musculoskeletal Health. Hormones are not simply an adjunct to osteoporosis prevention — they are among the most effective interventions available. The Baik et al. 2024 Menopause study found that estrogen monotherapy beyond age 65 was associated with a 15% reduction in fracture risk and a 7% reduction in osteoporosis risk.⁴ The original WHI fracture trial by Cauley et al. confirmed that combined hormone therapy significantly reduced fracture and bone mineral density loss in postmenopausal women.⁵ Equally important and less discussed: estrogen preserves muscle mass and protects against sarcopenia — the progressive loss of muscle function that underlies fall risk, reduced mobility, and loss of independence in older women.

Inflammation and Metabolic Health. Estrogen deficiency accelerates low-grade systemic inflammation — the same inflammatory state linked to cardiovascular disease, type 2 diabetes, dementia, and certain cancers. Estrogen regulates immune function, reduces inflammatory cytokines, and helps maintain the epithelial barriers that limit chronic inflammatory activation. Progesterone complements these anti-inflammatory effects. When hormones decline and this protective mechanism is withdrawn, the downstream metabolic consequences are significant — and they don’t announce themselves as hormonal in origin.

The Clinical Blind Spot

A woman who presents with cognitive complaints gets a neurology referral. One with fragility fractures gets a DEXA scan and a bisphosphonate. One with chronic low-grade inflammation and metabolic dysfunction gets a statin and a diabetes screening. Each symptom cluster is managed in isolation, by a different specialist, while the underlying hormonal trajectory goes unaddressed.

This is not a failure of clinical intention. It is a failure of clinical training. Most providers were not taught to see hormone decline as a systems-level driver of disease. They were taught to see it as a reproductive transition with some manageable symptoms.

What the Evidence Now Supports

The 2024 data is unambiguous. Manson et al. found that estrogen therapy alone was associated with a 19% reduction in overall mortality.¹ Baik et al. documented risk reductions across cardiovascular, oncologic, neurological, and skeletal outcomes in women over 65 — a population previously considered outside the treatment window.⁴ The evidence base for appropriately prescribed BHRT — with estrogen and testosterone delivered via non-oral routes and progesterone prescribed in its oral bioidentical form — has never been stronger.

The providers best positioned to act on this evidence are those who understand not just what to prescribe, but why — the mechanisms, the timing, the monitoring, and the meaningful distinction between bioidentical and synthetic hormones.

Closing the Gap

National Women’s Health Month is a reminder that women deserve care that reflects the current science — not a risk narrative from 2002. For providers, that means expanding the clinical lens: hormones are not a niche specialty. They are a foundational element of women’s health across the lifespan.

The BHRT Training Academy gives providers the evidence-based framework to deliver that level of care — from understanding the multi-system role of hormones to building protocols that produce real outcomes. If you’re ready to move beyond symptom management and into the science of hormone-driven health, your training starts here.

 References

1. Manson JE, Aragaki AK, Bassuk SS, et al. Benefits of lower-dose and non-oral hormone replacement therapy. JAMA. 2024;331(4):357–369.
2. U.S. Food & Drug Administration. HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. November 10, 2025. https://www.fda.gov/news-events/press-announcements/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy
3. Hamoda H, Panay N, Arya R, Savvas M. The British Menopause Society & Women’s Health Concern 2020 recommendations on hormone replacement therapy in menopausal women. Post Reproductive Health. 2020;26(4):181–209.
4. Baik SH, Baye F, McDonald CJ. Use of menopausal hormone therapy beyond age 65 years and its effects on women’s health outcomes by types, routes, and doses. Menopause. 2024;31(5):363–371.
5. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA. 2003;290(13):1729–1738.